Zimmer Biomet Holdings, Inc. (ZBH) · Aug 5, 2026 · Company update

Revenue beat and growth outlook rises, but margins lag

Revenue beat and growth outlook rises, but margins lag

The quarter cleared published expectations, led by sales rather than earnings. Net sales were $2.177 billion, above the published consensus range of roughly $2.13 billion-$2.16 billion, while adjusted EPS of $2.07 exceeded the roughly $2.01-$2.03 expectation. The more consequential update is the full-year revenue outlook: the midpoint for organic constant-currency growth rose 75 basis points to 2.75%, signaling management sees better underlying demand than it did three months ago. (Geographic and Product Category Sales; Financial Guidance)

MetricQ2 2026 actualQ2 2025 / published expectationRead-through
Net sales$2.177B$2.077B; consensus roughly $2.13B-$2.16B4.8% reported growth; modest revenue beat (Condensed Consolidated Statements of Earnings)
Organic constant-currency sales growth4.0%—Above the updated full-year 2.25%-3.25% outlook (Sales-change reconciliation; Financial Guidance)
Adjusted diluted EPS$2.07$2.07; consensus roughly $2.01-$2.03Small beat, but no year-over-year adjusted EPS growth (Reconciliation of Reported to Adjusted Results)
Adjusted operating margin25.7%27.8%Down 210 basis points despite the sales increase (Adjusted Operating Profit & Margin)
Full-year organic constant-currency growth outlook2.25%-3.25%1.0%-3.0% previouslyMidpoint raised 75 basis points (Financial Guidance)
Full-year adjusted EPS outlook$8.47-$8.59$8.40-$8.55 previouslyMidpoint raised $0.06, a comparatively modest lift (Financial Guidance)
Q2 free cash flow$308.3M$247.7MCash conversion improved year over year (Free Cash Flow reconciliation)

The guidance raise makes this better than a one-quarter beat. Reported revenue growth guidance moved to 3.9%-4.9% from 2.5%-4.5%, and constant-currency growth moved to 3.4%-4.4% from 2.0%-4.0%. Because the organic outlook also rose, the improvement is not merely currency or the Paragon 28 acquisition contribution. (Financial Guidance)

The limitation is profitability: stronger sales are not yet producing operating leverage. Adjusted operating profit fell to $559.7 million from $578.5 million, and adjusted margin contracted to 25.7% from 27.8%. Flat adjusted EPS therefore understates neither a collapse nor a clean earnings acceleration: the company delivered more revenue but less adjusted operating profit, with the quarterly EPS beat comparatively narrow. (Adjusted Operating Profit & Margin; Reconciliation of Reported to Adjusted Results)

Growth was uneven beneath the headline. Hips grew 5.1% and Technology & Data, Bone Cement and Surgical grew 21.5% organically in constant currency, while total Knees were essentially flat at 0.1%; international Knees declined 1.5%. That mix supports the raised outlook, but it also shows the core knee franchise was not the source of the quarter's upside. (Geographic and Product Category Sales)

Cash flow and buybacks add support, though they do not solve the margin issue. Second-quarter free cash flow increased 24% to $308.3 million, and the company lifted planned 2026 repurchases to up to $1 billion. It had already repurchased $500.8 million of stock in the first half, while net debt edged up to $7.069 billion as cash declined. (Free Cash Flow reconciliation; Condensed Consolidated Statements of Cash Flows; Debt to Net Debt reconciliation)

Original filing on SEC EDGAR

More Zimmer Biomet Holdings, Inc. news

Revenue beat and growth outlook rises, but margins lag | ZBH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.